Keyphrases
Active Malignancy
24%
Acute Outcome
27%
Acute Pulmonary Embolism
24%
Adjusted Hazard Ratio
36%
Arterial Variants
24%
Atherosclerotic Vascular Disease
24%
Atrial Fibrillation
100%
Blood Pressure
26%
Cardiovascular Events
28%
Cardiovascular Mortality
31%
Cardiovascular Outcomes
28%
Cardiovascular Risk
35%
Cardiovascular Safety
27%
Confidence Interval
61%
Diagnosis Treatment
24%
Diastolic Blood Pressure
24%
Edoxaban
31%
Endovascular Aneurysm Repair
24%
Female Sex
24%
General Anesthesia
24%
High Cardiovascular Risk
27%
High Risk
25%
High-risk Pulmonary Embolism
48%
Independent Risk Factors
27%
Lorcaserin
48%
Major Adverse Cardiovascular Events
38%
Malignancy
24%
Mechanical Thrombectomy
48%
Metabolic Effects
24%
Myocardial Infarction
62%
Nave
27%
Net Clinical Outcome
29%
Non-vitamin K Antagonist Oral Anticoagulants
55%
Obese Patients
34%
Overweight or Obesity
34%
Overweight Patient
34%
Possible Mechanisms
24%
Pulmonary Embolism
51%
Risk Factors for Stroke
24%
Ruptured Abdominal Aortic Aneurysm (rAAA)
30%
Stroke Prevention in Atrial Fibrillation
24%
Systolic Blood Pressure
27%
Thrombolysis in Myocardial Infarction
26%
Type 2 Diabetes Mellitus (T2DM)
24%
Vascular Disease
27%
Vascular Genes
24%
Vascular Quality Initiative Database
24%
Venous Thromboembolism
27%
Vitamin K Antagonists
41%
Warfarin
57%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Coronary Syndrome
24%
Adverse Event
11%
Adverse Outcome
24%
All Cause Mortality
5%
Anacetrapib
24%
Anticoagulant Agent
45%
Antivitamin K
53%
Atrial Fibrillation
100%
Biological Marker
13%
Bleeding
12%
Brain Ischemia
12%
Brain Natriuretic Peptide
10%
Cardiovascular Disease
31%
Cardiovascular Risk
44%
Cerebrovascular Accident
52%
Chronic Kidney Failure
15%
Clinical Trial
6%
Congestive Heart Failure
27%
Coronary Artery Disease
6%
Dabigatran
24%
Darapladib
24%
Diabetes Mellitus
5%
Diseases
10%
Edoxaban
31%
Heart Infarction
89%
Heart Muscle Injury
8%
High Density Lipoprotein Cholesterol
20%
Interleukin 6
24%
Lorcaserin
48%
Low Density Lipoprotein Cholesterol
12%
Maturity Onset Diabetes of the Young
24%
Placebo
44%
Randomized Clinical Trial
24%
Recurrent Disease
6%
Saxagliptin
8%
Serotonin 2C Agonist
6%
Severe Renal Impairment
24%
Statin (Protein)
8%
Thromboembolism
5%
Thrombosis
6%
Troponin T
8%
Unstable Angina Pectoris
6%
Vascular Disease
26%
Venous Thromboembolism
27%
Warfarin
58%
Medicine and Dentistry
Abdominal Aortic Aneurysm
32%
Acute Pulmonary Embolism
24%
Adverse Event
24%
Antithrombotic
48%
Aortic Disease
8%
Aortic Dissection
8%
Apoplexy
53%
Atrial Fibrillation
75%
Bicuspid Aortic Valve
8%
Blood Pressure
24%
Cardiovascular Risk
24%
Cardiovascular System
48%
Cell Signaling Pathway
8%
CHA2DS2-VASc Score
7%
Chronic Kidney Disease
15%
Clinical Guideline
8%
Clinical Trial
8%
Clinician
24%
Congestive Heart Failure
7%
Diastolic Blood Pressure
24%
Diseases
8%
Endovascular Aneurysm Repair
24%
Family Planning
8%
Fibromuscular Dysplasia
8%
General Anesthesia
24%
Genetic Screening
24%
Hazard Ratio
13%
Health Care Cost
16%
Hemodynamic
9%
Intensive Care Unit
9%
Invasive Diagnostics
24%
Kidney Function
12%
Local Anesthesia
10%
Major Bleeding
8%
Maturity Onset Diabetes of the Young
14%
Mechanical Thrombectomy
48%
Myocardial Infarction
16%
Outpatient
24%
Patient Care
8%
Patient with Diabetes
24%
Patient with Type 2 Diabetes
14%
Pulmonary Embolism
72%
Pulmonary Embolism Response Team
8%
Severe Renal Impairment
24%
Surgical Technique
24%
Systolic Blood Pressure
17%
Thoracic Aortic Aneurysm
8%
Vascular Disease
26%
Vitamin K Antagonist
48%
Warfarin
30%